For Researchers

The Foundation Fighting Blindness contributes millions of dollars per year to vision research projects being conducted at hospitals and universities across Canada.

These funds are distributed through our Operating Grant and Career Transition Award programs to exceptional research teams focused on understanding, preserving and restoring vision.

If you are a Canadian vision scientist interested in applying for one of our grant programs, please fill out the applicable forms below. All submissions are reviewed by our expert Scientific Advisory Board.

FFB Grants

Clinician-Scientist Emerging Leader Award

The Foundation Fighting Blindness Canada (FFB) Clinician-Scientist Emerging Leader Award aims to strengthen the community of clinician-scientists with ophthalmology expertise, who are ready to collaborate with key stakeholders and researchers across the vision research community. Clinician-scientists in training face pivotal challenges because they must balance clinical responsibilities with their developing research programs.

The award is designed to support clinician-scientists in training who have demonstrated a keen interest in forging an independent career in research that will complement their clinical practice. The award provides up to four years of research funding during residency and as an early faculty member. This support should help to facilitate the transition from the clinical training period into a new faculty appointment and independent clinical practice.

Please direct questions to Mary Sunderland, Director of Research & Education at

Forms and Applications:
2016 Guidelines for the Allocation of Funds 
Emerging Leaders: Call for Applications PDF
Emerging Leaders: Budget Module PDF

Application deadline: November 29, 2016

Submission Instructions
If your application file is larger than 5MB, please submit it using our Dropbox File Request. Be sure to include your name and institution as part of the file name.

If your application file is less than 5MB in size, please use the submit application button below. If you encounter issues when uploading, please contact

Clinician-Scientist Emerging Leader Award generously sponsored by:

Logo: BMO

Submit Application

All fields marked with an asterisk (*) are required

Name *
Email *
Institution *
Upload full application *

FFB Policies & Positions

Patent Rights Policy

Created and Implemented September 17, 2014

The Foundation Fighting Blindness (FFB) has implemented a patent rights policy for FFB-funded research. The policy can be downloaded here:


Stem Cell Research

Created March 22, 2010

Stem cell research holds promise for finding treatments for various retinal dystrophies. The Foundation Fighting Blindness (FFB) is committed to finding treatments for retinal dystrophies and supports stem cell research as per the Assisted Human Reproduction Act (AHRA), which became law in Canada in March 2004. The Act and its framework ensure the consistent and regulated conduct of research, which balances respect for human life and potential for modern science. The FFB acknowledges the highly sensitive and ethical issues addressed by the Act concerning embryonic stem cell research, and supports efforts to identify alternative sources for therapeutic applications. The FFB respects all points of view on this important topic.

For details about Assisted Human Reproduction in Canada visit

If you wish not to support embryonic stem cell research, your donation to the FFB can be directed to alternative sources for therapeutic applications, such as gene therapy or to education and public awareness.

Indirect Costs

Created May 2007

The Foundation Fighting Blindness does not provide funds for indirect costs associated with research. While the Foundation recognizes that these are indeed legitimate expenditures, we believe the funding of such costs is the responsibility of governments and/or research institutions – not donors.

The Foundation is a member in good standing of the Health Charities Coalition of Canada (HCCC). All HCCC members abide by this funding policy. See the HCCC position statement on indirect costs.